Endocrine Abstracts

Background: Extrapulmonary PD NECs carry a poor prognosis. Some studies suggest cisplatin is more appropriate for younger patients due to its increased potency and nephrotoxicity compared to carboplatin, but randomized trials are lacking. We aim to determine whether there is a difference in outcomes for cisplatin vs carboplatin while adjusting for possible confounding factors.Methods: We identified PD NEC patients at Mayo Clinic between 2000-2022. Kaplan...

Background: Peptide receptor radionuclide therapy (PRRT) is a form of targeted systemic radiopharmaceutical therapy that has been approved for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Persistent hematologic dysfunction is a recognized potential long-term toxicity after PRRT, including the development of hematologic malignancies and persistent cytopenias. Therapy-related myeloid neoplasms (t-MN) are a well-recognized entity that ...

Background: Lu177 has shown efficacy in advanced NET with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time. In this study, we aimed to assess the prevalence of CH in NET patients (pts) prior to Lu177 along with the incidence of cytopenia in NET pts treated with lu177 based on the CH status at baselineMet...

Background: Neuroendocrine neoplasms (NEN) are known to be associated with specific familial syndromes. However, the incidence of pathogenic germline variants (PGVs) in unselected NEN patients is unknown. In this study, we aim to determine the prevalence and clinical utility of PGVs in unselected NEN patients using universal a genetic testing approach.Methods: We undertook a prospective study of germline genetic testing using a > 80 gene next-generat...